跳至主要内容
临床试验/NL-OMON47701
NL-OMON47701招募中不适用

Feasibility of MRI-guided focal salvage high-dose-rate brachytherapy for locally recurrent prostate cancer - MRI-guided focal salvage HDR-BT for locally recurrent prostate cancer

niversitair Medisch Centrum Utrecht0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Age >=18 years
  • - Biopsy proven local recurrence
  • - Biopsy proven recurrence at least 2 years after primary radiotherapy
  • treatment (low-dose-rate brachytherapie or external beam radiation therapy)
  • - Limited and non-aggressive tumor presentation at time of salvage (Prostate
  • Spedific Antigen (PSA) at time of salvage <10)
  • - Prostate Specific Antigen (PSA) doubling time more than 12 months
  • - Acceptable toxicity of primary radiation treatment (International Prostate
  • Symptom Score (IPSS)<15)
  • - Tumour location technically feasible for brachytherapy
  • - Tumour on MRI and PSMA-PET scan within anatomical prostate borders (no
  • extracapsular growth or metastasis)
  • - Karnofsky score >=70
  • - Written informed consent
  • - Fit for spinal anaesthesia

排除标准

  • - Distant metastasis
  • - Severe toxicity during primary radiation treatment (International Prostate
  • Symptom Score (IPSS)>15)
  • - Patients who meet exclusion criteria for MRI following the protocol of the
  • radiology department of the UMC Utrecht
  • - Anticoagulant administration continuously required, except for Ascal
  • - Discongruence between prostate biopsies and contrast MR imaging
  • - No prior prostate cancer treatment(s) (like a recent TURP (<6 months before
  • focal salvage HDR treatment), HIFU, cryosurgery), except for radiotherapy

研究者

发起方
niversitair Medisch Centrum Utrecht

相似试验